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ABSTRACT
Background Few data exist on tuberculosis (TB)
incidence according to time from HIV seroconversion in
high-income countries and whether rates following
initiation of a combination of antiretroviral treatments
(cARTs) differ from those soon after seroconversion.
Methods Data on individuals with well estimated dates
of HIV seroconversion were used to analyse post-
seroconversion TB rates, ending at the earliest of 1
January 1997, death or last clinic visit. TB rates were
also estimated following cART initiation, ending at the
earliest of death or last clinic visit. Poisson models were
used to examine the effect of current and past level of
immunosuppression on TB risk after cART initiation.
Results Of 19 815 individuals at risk during 1982–
1996, TB incidence increased from 5.89/1000 person-
years (PY) (95% CI 3.77 to 8.76) in the ﬁrst year after
seroconversion to 10.56 (4.83 to 20.04, p=0.01) at
10 years. Among 11 178 TB-free individuals initiating
cART, the TB rate in the ﬁrst year after cART initiation
was 4.23/1000 PY (3.07 to 5.71) and dropped
thereafter, remaining constant from year 2 onwards
averaging at 1.64/1000 PY (1.29 to 2.05). Current CD4
count was inversely associated with TB rates, while nadir
CD4 count was not associated with TB rates after
adjustment for current CD4 count, HIV-RNA at cART
initiation.
Conclusions TB risk increases with duration of HIV
infection in the absence of cART. Following cART
initiation, TB incidence rates were lower than levels
immediately following seroconversion. Implementation of
current recommendations to prevent TB in early HIV
infection could be beneﬁcial.
INTRODUCTION
Active tuberculosis (TB) among HIV-positive indivi-
duals in high-income countries is of concern.
Although TB morbidity has fallen since combined
antiretroviral therapy (cART) became widely avail-
able,1 2 this reduction has not been as remarkable
as that observed for other opportunistic infections3
and TB may be diagnosed at relatively high current
and nadir CD4 cell counts.4 In addition, the risk of
TB in high-income countries is substantial even
after starting cART due to the increasing propor-
tion of migrants from high-burden TB areas, such
as sub-Saharan Africa.5–8 An additional concern
about TB is immune reconstitution inﬂammatory
syndrome (IRIS), an incompletely understood and
poorly quantiﬁed immunological phenomenon con-
sisting of a paradoxical worsening of previously
treated TB or the unmasking of subclinical TB in
the ﬁrst few months following cART initiation.9
Effective means to reduce and prevent TB
disease among HIV-positive individuals include
screening for latent TB, treatment for latent infec-
tion (TLI), and initiation of cART at CD4 count
thresholds as indicated by national and inter-
national guidelines.10–12 However, a clear under-
standing of the clinical epidemiology of TB risk at
all stages of HIV infection, particularly in early
infection, and how this differs from risk following
cART initiation is lacking but is needed to inform
healthcare personnel on the optimal timing of the
implementation of TB-preventive strategies.
Using data from HIV-positive individuals with
well estimated dates of HIV seroconversion, we
aimed to estimate TB incidence rates following
Key messages
What is the key question?
▸ Few data exist on tuberculosis (TB) incidence
according to time from HIV seroconversion in
high-income countries and whether rates
following combined antiretroviral therapy
(cART) initiation differ from those soon after
seroconversion. This information is important to
inform the optimal timing of implementation of
TB-preventive strategies.
What is the bottom line?
▸ In this study using CASCADE data on
HIV-positive individuals with well estimated
date of HIV seroconversion, we found that the
risk of TB in the absence of cART increases
with HIV infection duration and is lower after
cART initiation than the risk immediately
following HIV seroconversion.
Why read on?
▸ This study suggests that a more stringent
application of currently recommended
TB-preventive measures early in HIV infection
could help to reduce the TB burden in
high-income countries.
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HIV seroconversion and before cART initiation and to evaluate
whether the risk of TB following cART differs from the risk in
early HIV infection when the immune system is still relatively
intact. Finally, we wanted to explore the role of current and past
levels of immunosuppression on TB risk after cART initiation.
METHODS
Patients
We used data from CASCADE, a collaboration of 28 cohorts of
individuals with well estimated dates of HIV seroconversion
from Europe, Australia, Canada and sub-Saharan Africa.13 The
date of seroconversion was estimated by various methods, most
frequently as the midpoint of an interval of <3 years between a
negative and a positive HIV antibody test result; laboratory evi-
dence of seroconversion; the date of a seroconversion illness; or
the most likely date of infected factor VIII concentrate infusion
for haemophiliacs. As the study aims to quantify TB risk in high-
income countries, data from the sub-Saharan African cohorts
were excluded. Finally, individuals younger than 16 years at
seroconversion were excluded. Data were pooled in 2009
within EuroCoord (http://www.EuroCoord.net).
TB diagnosis
Only the ﬁrst TB diagnosis after entry into the cohort was
included. This was not necessarily the ﬁrst-ever TB episode per
patient. TB was classiﬁed as pulmonary or extrapulmonary.
Most TB diagnoses were deﬁnitive, deﬁned as having a positive
culture for Mycobacterium tuberculosis isolated from any clin-
ical sample (sputum, bronchial washings, pleural ﬂuid, lymph
node, bone marrow aspirate, cerebrospinal ﬂuid), and fewer
were presumptive, deﬁned as having clinical or radiological
signs suggestive of TB, other causes were excluded, and showing
a clinical response to TB treatment. Skin tests for M tuberculosis
infection and TLI were not systematically done in most of the
cohorts.
Statistical analyses
Risk of TB after HIV seroconversion in the pre-cART era
We computed TB incidence rates in the pre-cART era as the
number of ﬁrst-ever recorded TB events per 1000 person-years
(PY). Follow-up started at seroconversion or enrolment into a
cohort, whichever was later, and ended at the last visit to the
clinic, death, 1 January 1997 or TB diagnosis, whichever was
earliest. TB rates were computed by duration of HIV infection
in 1-year intervals and time-dependent current CD4 count cat-
egory (<200, 200–349, 350–499, ≥500 cells/mm3). Using all
available CD4 counts, we assumed a constant CD4 count from
the date of measurement until the date of the next measure-
ment. When a CD4 count was not followed by a subsequent
measurement within 6 months, the patient was excluded from
the risk set until a new CD4 count became available.
We conducted the following sensitivity analyses. As pulmon-
ary TB became an AIDS-deﬁning event in 1993, we recomputed
TB rates restricted to follow-up after 1 January 1993.14 As
cART was available before 1997 in some cohorts, follow-up
ended at 1 January 1996. Because of the uncertainty regarding
the date of seroconversion, we recomputed TB rates including
only patients with an HIV test interval <12 months. Finally, we
excluded TB events and time at risk within 30 days of cohort
enrolment.
Risk of TB after cART initiation
We computed TB incidence rates after cART initiation in indivi-
duals without TB with follow-up ending at death, last visit to
the clinic or TB diagnosis, whichever was earliest. We presented
TB rates by time-dependent duration of cART in years and
current CD4 count category (<200, 200–349, 350–499, ≥500
cells/mm3). To assess the impact of late cART initiation, we also
computed these rates separately by CD4 count category at cART
initiation (<50, 50–199, 200–349, 350–499, ≥500 cells/mm3).
Univariate Poisson models were used to examine the associ-
ation between TB rates after cART initiation and current and
past level of immunosuppression measured as time-dependent
current CD4 cell count, HIV-RNA, nadir, time-weighted
average CD4 count and duration of HIV infection at cART initi-
ation. These variables were included in a multivariable model,
adjusting for the following potential confounders chosen a
priori: risk group, sex, current age, calendar year of cART initi-
ation (<2001 or ≥2001), and geographical region of origin.
The latter was categorised as follows: very high incidence
region: sub-Saharan Africa; high–mid risk regions: Eastern
Europe, Central Asia, North Africa, South Asia, East Asia and
the Caribbean; mid–low risk regions: Western Europe, Middle
East, the Americas and Oceania; and unknown. The results
were presented from a reduced model, including all covariates
measuring current and past level of immunosuppression and
potential confounding variables signiﬁcant at the 10% level in
the univariate analysis. To explore if current CD4 count was an
independent predictor of TB risk after accounting for virological
status, we reﬁt the ﬁnal model adjusting for current log10
HIV-RNA.
Average CD4 cell count was estimated as the area under the
CD4 count curve before cART initiation against time. Then, the
time-weighted average was obtained by dividing the area under
the curve by duration of follow-up since seroconversion.15
TB diagnoses occurring on the same date as cART initiation
were excluded. To avoid selective drop-out of patients failing to
respond to cART, we assumed that, once started, patients
remained on treatment.
cART was deﬁned as a combination of at least three drugs
from at least two classes or at least three nucleoside reverse-
transcriptase inhibitors, one of which was tenofovir or abacavir.
As TB risk during treatment interruption could be higher due
to virological rebound, we recomputed TB rates while patients
were known to be off cART after interruption deﬁned as at least
15 days without any treatment.
Data were analysed using STATAV.11.0.
RESULTS
Patients’ characteristics
Of 19 815 patients in CASCADE, we included 9175 and
11 178 patients at risk of TB in the pre-cART era and after
cART initiation, respectively. A total of 4575 patients contribu-
ted follow-up data to both analyses. Most patients were men
who acquired HIV through sex with men and originated from
low-burden TB countries (table 1). In the pre-cART era the pro-
portion of patients originating from high-burden TB areas
varied from 4% in France and Norway to <1% in Greece and
Italy.
Risk of TB following HIV seroconversion in the pre-cART era
Of 9175 patients at risk during 1982–1996 with median age of
36 years (IQR 31–42), 243 were diagnosed with TB during
35 906 PY. These men presented with a median CD4 cell count
of 125 cells/mm3 (IQR 40–286) and duration of infection of
3.4 years (IQR 1.1–7.3) at TB diagnosis.
Figure 1A presents TB incidence rates according to duration
of HIV infection. Although the risk decreased in the ﬁrst 3 years
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following seroconversion, overall TB rates increased from 5.9/
1000 PY (95% CI 3.77 to 8.76) in the ﬁrst year following HIV
seroconversion to 10.6/1000 PY (4.83 to 20.04) at 10 years (test
for trend p<0.001). TB rates were 21.9 events/1000 PY (17.9
to 26.6), 6.4 (4.5 to 8.9), 3.2 (1.9 to 5.0), 3.3 (2.3 to 4.8) and
5.4 (4.0 to 7.1) for current CD4 count categories of <200,
200–349, 350–500, ≥500 cells/mm3 and missing CD4 count,
respectively. The proportion of follow-up with unknown CD4
count was 26%. Median (IQR) duration of HIV infection in
years was 5.7 (4.0–7.6), 5.0 (3.2–7.2), 4.0 (2.3–6.1), 3.2 (1.8–
5.2), 2.4 (1.0–4.1) and 3.0 (1.7–5.1) for current CD4 categories
of <50, 50–199, 200–349, 350–500, ≥500 cells/mm3 and
missing CD4 count, respectively.
Similar TB rates were found when the 33 TB cases diagnosed
on the date of enrolment were excluded, when individual
follow-up was ended at 1 January 1996 and when the analyses
were restricted to patients with an HIV test interval
<12 months. The TB rate in the ﬁrst year following seroconver-
sion was 8.9 (95% CI 5.0 to 14.8) per 1000 PY when pre-1993
follow-up was excluded, somewhat higher than that estimated in
the main analysis.
Incidence of TB after cART initiation
There were 11 178 patients without TB who started cART at a
median CD4 count of 320 cells/mm3 (IQR 210–470), mostly
(61%) with a combination including a protease inhibitor. Of
these, 120 were diagnosed with TB during 57 104 PY at a
median CD4 count of 195 cells/mm3 (IQR 55–419) and log10
HIV-RNA of 4.2 log10 copies/ml (IQR 1.8–5.3) (table 1). The
Table 1 Characteristics of patients at risk of tuberculosis in the pre-cART era (before1 January 1997) and after cART initiation
Before 1 January 1997 After cART initiation
Number at risk of TB 9175 11178
Total person-years of follow-up 35906 57104
Number of TB diagnoses 243 120
TB as first AIDS-defining events 184 100
Number of pulmonary TB diagnoses 154 (63%) 74 (64%)
Incidence rate of TB (95% CI) per 1000 person-years 6.8 (5.9 to 7.7) 2.2 (1.7 to 2.5)
Median (IQR) CD4 count at TB diagnosis, cells/mm3 125 (40–286) 195 (55–419)
Median (IQR) HIV-RNA at TB diagnosis, log10 copies/ml* – 4.2 (1.8–5.3)
Median (IQR) HIV test interval, years† 0.8 (0.4–1.3) 0.8 (0.3–1.4)
Number of TB diagnoses Number of TB diagnoses
Risk group
Sex between men 4587 (50%) 76 6253 (56%) 46
Sex between women and men 1691 (18%) 31 2904 (26%) 34
Injecting drug use 2376 (26%) 118 1506 (13%) 37
Other/unknown 524 (6%) 18 515 (5%) 3
Women 2006 (22%) 48 2449 (22%) 31
Geographical origin‡
Mid–low TB incidence§ 6350 (69%) 197 7907 (71%) 88
High–mid TB incidence¶ 202 (2%) 17 339 (3%) 7
Very high TB incidence: sub-Saharan Africa 126 (1%) 9 495 (4%) 8
Unknown 2500 (27%) 30 2437 (22%) 17
4575 patients contributed to both analyses.
*HIV-RNA not routinely performed before 1997.
†Time between last negative and first positive HIV antibody test dates.
‡All patients are in care in high-income countries.
§Mid–low incidence regions: Western Europe, North America, Oceania, Middle East and Latin America.
¶High–mid incidence regions: Eastern Europe, Central Asia, North Africa, South Asia, East Asia and the Caribbean.
cART, combination antiretroviral therapy; TB, tuberculosis.
Figure 1 Trends in incidence rates
(with 95% CIs) of tuberculosis
according to (A) duration of HIV
seroconversion in the pre-combination
antiretroviral therapy (cART) era and
(B) time since initiation of cART. CIs
(as shown by error bars) were
computed assuming a Poisson
distribution for the number of events.
PY, patient-years.
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overall TB incidence rate after cART initiation was 2.1/1000 PY
(95% CI 1.7 to 2.5).
Trends of TB rates according to time since cART initiation are
presented in ﬁgure 1B. Although TB rates increased in the ﬁrst
2 months following cART initiation, they dropped from 4.2/
1000 PY (95% CI 3.1 to 5.7) in the ﬁrst year after cART initi-
ation and remained constant thereafter (average rate from year 2
onwards 1.64/1000 PY; 95% CI 1.29 to 2.05). The trend of
initial increase in TB incidence was particularly remarkable in
patients who initiated cART at CD4 <50 cells/mm3 (ﬁgure 2).
The proportion of total follow-up spent with CD4 count ≥500
was 49.4% and TB rate at these CD4 levels was 0.9/1000 PY
(95% CI 0.5 to 1.4). Median (IQR) nadir and time-weighted
average CD4 cell count and duration of HIV infection at cART
initiation were 260 cells/mm3 (169–367), 419 cells/mm3 (309–
546) and 3.42 years (1.05–7.30), respectively.
TB incidence during treatment interruption was 2.2 events/
1000 PY (95% CI 1.2 to 3.8). When we excluded TB events
occurring within the ﬁrst 30 days after cART initiation, the TB
rate in the ﬁrst year was 4.22/1000 PY (95% CI 3.00 to 5.76).
Effect of current and past level of immunosuppression on
the incidence of TB following cART initiation
While lower CD4 nadir and time-weighted average CD4 count
at cART initiation were associated with increased TB risk in the
univariate analyses (p values 0.011 and 0.031, respectively),
there was no evidence they were independent predictors after
adjusting for current CD4 count. In the ﬁnal multivariable
model, higher current CD4 count category and lower HIV-RNA
at cART initiation were signiﬁcantly associated with lower TB
incidence (table 2). Being an injecting drug user was associated
with increased risk of TB following cART initiation. In the
model including current HIV-RNA, current CD4 count and
current HIV-RNA were independent predictors of TB risk after
cART initiation (p values 0.01 and 0.001, respectively) (results
not shown).
DISCUSSION
In this study of individuals followed up since HIV seroconver-
sion in high-income countries we found that the risk of TB
increases with HIV infection duration in the pre-cART era, is
lower after cART initiation than the risk immediately following
seroconversion, and is strongly associated with current CD4
count, not past levels, once cART is initiated.
The ﬁnding that the risk of TB increases with duration of
HIV infection is in agreement with previous reports from
smaller cohorts from the Netherlands,16 Spain17 and South
Africa18 and suggests that HIV-positive patients would beneﬁt
from TB prevention being implemented at an early stage. The
trend of relatively high TB risk in the ﬁrst year and of decreas-
ing risk in the 2–3 years following seroconversion could be
explained by an increased risk of reactivation of latent TB
during primary HIV infection. Alternatively, this could be an
artefact due to the uncertainty around the date of HIV serocon-
version. This is unlikely, however, as analyses in patients with an
HIV test interval <12 months showed similar patterns of TB
risk in early infection. Animal models19 and in vitro studies20
suggest that, during early HIV infection, M tuberculosis-speciﬁc
CD4 T cells may be selectively depleted, resulting in a rapid
increase in the risk of developing active TB immediately follow-
ing seroconversion. Moreover, this defect in functional anti-
mycobacterial immunity can only be partially restored by
ART.21 Unfortunately, we were unable to explore the impact of
seroconversion on TB risk since we have no information on the
risk before seroconversion. Therefore, any TB events occurring
between HIV acquisition and HIV diagnosis may have been
missed, although this is unlikely to be a major source of bias.
Figure 2 Trends in incidence rates of tuberculosis according to time since initiation of combination antiretroviral therapy (cART) and CD4 count at
cART initiation.
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We found that the TB incidence rate after cART initiation
(2 events/1000 PY) was lower than the rate observed during the
ﬁrst year after seroconversion, when the immune system was still
relatively intact (ranging from 6 to 9/1000 PY). This result could
indicate that the beneﬁcial effect of cART on restoration of
TB-speciﬁc defence cannot be solely estimated by measuring abso-
lute CD4 counts in peripheral blood and that viral suppression
restores other immune functions. This has been observed for other
opportunistic diseases, such as Pneumocystis jirovecii pneumonia.22
We found that the risk of TB after cART initiation remained
substantial, as the TB rate after cART initiation with current
CD4 >500 cells/mm3 was 0.9 events/1000 PY (95% CI 0.5 to
1.4). This is higher than rates estimated by WHO for the
general population, which ranged from 0.05 to 0.2/1000 PY in
the same high-income countries (WHO 2010).23 This high rate
could be explained by factors such as incomplete immune recov-
ery which may favour reactivation of persisting latent infection,
increased risk of exposure to TB in healthcare facilities, and/or
the presence of a large proportion of HIV-positive patients from
high TB-burden countries or injecting drug users.
To our knowledge, this is the largest study examining the
association between current or previous immunosuppression
and the risk of TB after cART initiation. While nadir CD4
count is a marker if the risk of TB is increased by previous
immune system damage, even after subsequent immunological
recovery, time-weighted average CD4 count is a summary
measure of the overall immunodeﬁciency history. Current CD4
count and HIV RNA at cART initiation were the dominant pre-
dictors of TB risk and we found no association between
markers of past history of immunosuppression, such as duration
of infection, nadir and time-weighted average CD4 count at
cART initiation. We also found that higher current HIV-RNA in
the same CD4 count strata was associated with increased TB
risk. Therefore, in addition to an increase in CD4 counts, sup-
pression of viral replication seems to be important for immuno-
logical control of latent TB infection in patients on cART.
Table 2 Factors associated with TB incidence after cART initiation
Univariate model Final adjusted model
IRR 95% CI p* IRR 95% CI p*
Risk group <0.001 0.002
Sex between men 1 (ref) 1 (ref)
Sex between men and women 1.67 (1.07 to 2.61) 1.58 (0.78 to 3.21)
Injecting drug users 3.34 (2.17 to 5.15) 4.26 (2.18 to 8.33)
Other/unknown 0.85 (0.27 to 2.75) 1.05 (0.24 to 4.59)
Geographical origin 0.008 0.031
Mid–low TB incidence† 1 (ref) 1 (ref)
High–mid TB incidence‡ 1.91 (0.93 to 3.93) 2.14 (0.76 to 5.99)
Very high TB incidence: sub-Saharan Africa 1.90 (0.89 to 4.15) 2.69 (0.95 to 7.64)
Unknown 0.56 (0.33 to 0.94) 0.42 (0.17 to 1.08)
Duration of HIV infection at cART initiation (years) 1.03 (0.98 to 1.07) 0.241 1.01 (0.93 to (1.09) 0.869
Current CD4 count <0.001 <0.001
≥500 1 (ref) 1 (ref)
350–499 1.89 (1.00 to 3.58) 1.69 (0.74 to 3.84)
200–349 2.58 (1.38 to 4.83) 2.24 (0.97 to 5.18)
<200 15.4 (9.24 to 25.5) 11.57 (5.58 to 23.96)
Nadir CD4 count at cART initiation 0.011 0.109
≥500 1 (ref) 1 (ref)
350–499 1.04 (0.53 to 2.03) 1.12 (0.74 to 3.84)
200–349 1.19 (0.69 to 2.04) 1.77 (0.97 to 5.18)
<200 2.02 (1.23 to 3.32) 2.64 (0.74 to 3.84)
Time-weighted average CD4 at cART initiation 0.031 0.4316
≥500 1 (ref) 1 (ref)
350–499 0.85 (0.53 to 1.38) 0.52 (0.21 to 1.14)
200–349 1.31 (0.83 to 2.07) 0.71 (0.29 to 1.72)
<200 2.05 (1.19 to 3.54) 0.60 (0.18 to 1.99)
HIV-RNA at cART initiation (1 log increase) 1.16 (1.04 to 1.29) 0.006 1.118 (1.04 to 1.33) 0.007
Current age (10-year increase) 1.01 (0.83 to 1.22) 0.941
Sex 0.269
Men 1
Women 1.26 (0.84 to 1.90)
Calendar year at cART initiation 0.586
<2001 1
≥2001 0.9 (0.60 to 1.35)
*Wald test for heterogeneity when variable is categorical. Multivariable Poisson model for the association of TB risk and past and current level of immunosuppression (current CD4
count, nadir and time weighted average CD4 count and duration of HIV infection at cART initiation) adjusted for risk group, geographical origin and HIV-RNA at cART initiation.
†Mid–low incidence regions: Western Europe, North America, Oceania, Middle East and Latin America.
‡High–mid incidence regions: Eastern Europe, Central Asia, North Africa, South Asia, East Asia and the Caribbean.
cART, combination antiretroviral therapy; IRR, incidence rate ratio; TB, tuberculosis.
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Consistent with previous reports,24–26 we observed an
increase in TB risk immediately following cART initiation, espe-
cially in patients who were started on cART at CD4 <50 cells/
mm3. As screening for TB before ARTwas not standard practice
in the CASCADE cohorts, the high initial TB rates could be
partly explained by more intensive clinical evaluation in patients
starting cART, increasing the chance of diagnosis of prevalent
undiagnosed TB.27 Alternately, some of these events may be due
to unmasking of subclinical active infections by IRIS, a common
phenomenon after cART initiation in patients with TB infection
and low CD4 counts. As CASCADE does not collect clinical
data on TB diagnoses, we could not identify the relevant IRIS
cases. Nevertheless, the increase in risk following cART suggests
that screening for latent and active TB before cART and TLI in
patients with positive skin test, as recommended by national and
international guidelines, could be beneﬁcial.26
Our study has several limitations. First, we had no informa-
tion on TLI. As TLI has been shown to effectively reduce the
risk of active TB in patients coinfected with HIV,11 28 we could
have underestimated the risk. However, this is unlikely to have
occurred as, with the exception of the Swiss HIV cohort, TLI is
rarely provided to patients with HIV in the countries contribut-
ing data to the analysis.
Second, we did not have information on treatment adherence
and assumed that patients remained on therapy once it was
initiated. If diagnoses of TB are largely occurring in individuals
who have stopped cART or have poor adherence, then the TB
incidence after cART initiation would have been overestimated.
Nevertheless, our estimates are likely to be robust because we
found similar estimates of TB rates after cART initiation when
we only included individual follow-up time while patients were
known to be on cART.
Third, a relatively large proportion of follow-up in the
pre-cART era was spent with unknown CD4 cell count. Median
duration of HIV infection when CD4 count was unknown was
3 years, suggesting that we might have underestimated the risk
of TB at high CD4 count in the pre-cARTera.
Fourth, to avoid informative censoring due to ART initiation,
we estimated the TB risk in cART-naïve patients restricting ana-
lyses to the pre-cART era. TB exposure could have increased in
the last decade because of increasing numbers of migrants from
high-burden TB areas. However, the decreasing TB risk among
patients taking cART may have reduced the risk of acquiring TB
from patients visiting the same clinic.
Finally, when we compared TB risk between patients in the
pre-cART era with the risk after cART initiation our estimates
may have been biased through confounding by indication (ie,
patients who start cART are more likely to be sicker and at
higher TB risk). This would have led to an overestimate of the
risk of TB among those who initiated cART and would thus
tend towards estimating similar rates in the pre-cART era and
after cART initiation. Of note, we observed a lower TB risk
after cART, despite this potential bias.
In conclusion, in this study of patients with a well estimated
date of HIV seroconversion, we found that TB risk increases
from early HIV infection. More stringent diagnosis and treat-
ment of latent TB early in HIV infection could therefore help
to reduce the TB burden in high-income countries. This
would also beneﬁt patients not yet eligible for cART according
to current treatment guidelines. Finally, as the TB risk after
cART initiation is lower than the risk in cART-naïve indivi-
duals, access to cART and implementation of effective TB
treatment is essential in reducing the TB risk in high-income
countries.
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